nintedanib and Dermatitis

Nintedanib, a receptor tyrosine kinase (RTK) inhibitor has been developed as therapeutics for idiopathic pulmonary fibrosis and non-small lung cancer. We found that the expression levels of RTK, especially VEGFR1 is increased in skin biopsies of dermatitis patients from multiple independent datasets. Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Interestingly, nintedanib alleviates dermatitis symptom in OXA-induced animal model. Especially, levels of epidermis thickness, infiltrated immune cells including mast cells and eosinophils were decreased from mice cotreated with nintedanib and OXA compared with OXA treated mice. Moreover, serum IgE and Th2 cytokines including IL-4 and IL-13 were decreased by nintedanib treatment. These results suggest an evidence that nintedanib alleviates animal model of dermatitis.

Topics: Animals; Biomarkers; Biopsy; Cell Line; Cell Survival; Dermatitis; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression; Immunoglobulin E; Indoles; Mice; Oxazolone; Protein Kinase Inhibitors; Skin; Vascular Endothelial Growth Factor Receptor-1